Pathways
Role of Anti-CD47 mAb on Cancer Cells
Description:
Cancer continues to be a formidable challenge in the field of medical science, necessitating innovative therapeutic strategies to combat its relentless progression. The emergence of immunotherapy has brought about a paradigm shift in cancer treatment, harnessing the body's own immune system to recognize and destroy malignant cells. Among these immunotherapeutic approaches, the utilization of monoclonal antibodies (mAbs) targeting various cell surface markers has gained significant attention. O...
References:
-
Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma.
Cell. 2010 Sep 3;142(5):699-713. doi: 10.1016/j.cell.2010.07.044. -
Macrophages are critical effectors of antibody therapies for cancer.
MAbs. 2015;7(2):303-10. doi: 10.1080/19420862.2015.1011450. -
The CD47-SIRPĪ± Immune Checkpoint.
Immunity. 2020 May 19;52(5):742-752. doi: 10.1016/j.immuni.2020.04.011. -
Blocking CD47 efficiently potentiated therapeutic effects of anti-angiogenic therapy in non-small cell lung cancer.
. J Immunother Cancer. 2019 Dec 11;7(1):346. doi: 10.1186/s40425-019-0812-9.
You can view details of this pathway by subscribing:
9853 Pacific Heights Blvd.
Suite D., San Diego, CA 92121, USA
Tel: 858-224-2869
Fax: 858-205-1192
info@proteinlounge.com
Databases
Tools
Institutional License
Need our databases and tools to be availed by your whole university or institute? We recommend signing up for our Site License.
To set up a license, please contact: info@proteinlounge.com
Copyright © Protein Lounge Inc.
Terms & Conditions